tbuckley/cabot-search huggingface dataset:
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Authors: Laura M. Spring, Hyo Han, Minetta C. Liu, Erika Hamilton, Hanna Irie, Cesar A. Santa-Maria, James Reeves, Peng Pan, Ming Shan, Yongqiang Tang, Julie R. Graham, Sebastien Hazard, Leif W. Ellisen, Steven J. Isakoff
Journal: Nature Cancer (2022)

Abstract This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA -mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.
A novel Peng’s test in reducing bile leakage after partial hepatectomy for hepatocellular carcinoma: From an animal study to a clinical cohort Propensity score matching comparative study
Authors: Shutian Mo, Yongfei He, Guangzhi Zhu, Hao Su, Chuangye Han, Xinping Ye, Xiwen Liao, Chengkun Yang, Tianyi Liang, Zijun Chen, Yongguang Wei, Zhongliu Wei, Jianzhu Luo, Jusen Nong, Wan Yee Lau, Tao Peng
Journal: International Journal of Surgery (2022)
Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
Authors: Daniela Skalt, Bernhard Moertl, Michael von Bergwelt-Baildon, Christian Schmidt, Wolfgang Schoel, Veit Bücklein, Tobias Weiglein, Martin Dreyling, Karin Berger
Journal: HemaSphere (2022)

The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) from the German third-party payer perspective. A budget impact model was established over a 6-year period. Estimation of the third-line population: partitioned survival model based on outcome data from peer-reviewed literature, a top-down approach based on population forecasts, and age-standardized incidences. Cost data were derived from the controlling department of a tertiary hospital and a German cost-of-illness study. In the scenario analysis, the budget impact of treating second-line DLBCL patients was calculated. One-way deterministic sensitivity analyses were conducted to test the robustness of the model. For the period 2021-2026, 788-867 (minimum population, min) and 1,068-1,177 (maximum population, max) adult third-line r/r DLBCL patients were estimated. The budget impact ranged from €39,419,562; €53,426,514 (min; max) in year 0 to €122,104,097; €165,763,001 (min; max) in year 5. The scenario analysis resulted in a budget impact of €65,987,823; €89,558,611 (min; max) and €204,485,031; €277,567,601 (min; max) for years 0 and 5, respectively. This budget impact analysis showed a significant but reasonable financial burden associated with CAR T-cell therapy for a limited number of patients requiring individualized care. Further, this study presents challenges and future needs in data acquisition associated with cost analysis in personalized medicine. For comprehensive economic discussions, complementary cost-effectiveness analyses are required to determine the value of innovative therapies for r/r DLBCL.
Author Correction: Improving polygenic prediction in ancestrally diverse populations
Authors: Yunfeng Ruan, Yen-Feng Lin, Yen-Chen Anne Feng, Chia-Yen Chen, Max Lam, Zhenglin Guo, Yong Min Ahn, Kazufumi Akiyama, Makoto Arai, Ji Hyun Baek, Wei J. Chen, Young-Chul Chung, Gang Feng, Kumiko Fujii, Stephen J. Glatt, Kyooseob Ha, Kotaro Hattori, Teruhiko Higuchi, Akitoyo Hishimoto, Kyung Sue Hong, Yasue Horiuchi, Hai-Gwo Hwu, Masashi Ikeda, Sayuri Ishiwata, Masanari Itokawa, Nakao Iwata, Eun-Jeong Joo, Rene S. Kahn, Sung-Wan Kim, Se Joo Kim, Se Hyun Kim, Makoto Kinoshita, Hiroshi Kunugi, Agung Kusumawardhani, Jimmy Lee, Byung Dae Lee, Heon-Jeong Lee, Jianjun Liu, Ruize Liu, Xiancang Ma, Woojae Myung, Shusuke Numata, Tetsuro Ohmori, Ikuo Otsuka, Yuji Ozeki, Sibylle G. Schwab, Wenzhao Shi, Kazutaka Shimoda, Kang Sim, Ichiro Sora, Jinsong Tang, Tomoko Toyota, Ming Tsuang, Dieter B. Wildenauer, Hong-Hee Won, Takeo Yoshikawa, Alice Zheng, Feng Zhu, Lin He, Akira Sawa, Alicia R. Martin, Shengying Qin, Hailiang Huang, Tian Ge
Journal: Nature Genetics (2022)
FRET as the tool for in vivo nanomedicine tracking
Authors: Norraseth Kaeokhamloed, Samuel Legeay, Emilie Roger
Journal: Journal of Controlled Release (2022)

Advanced drug delivery system utilizing a nanocarrier is the major application of nanotechnology on pharmacotherapeutics. However, despite the promising benefits and a leading trend in pharmaceutical research, nanomedicine development suffers from a poor clinical translation problem as only a handful of nanomedicine products reach the market yearly. The conventional pharmacokinetic study generally focuses only on monitoring the level of a free drug but ignores the nanocarrier's role in pharmacokinetics. One hurdle is that it is difficult to directly track intact nanocarriers in vivo to explore their pharmacokinetics. Although several imaging techniques such as radiolabeling, nuclear imaging, fluorescence imaging, etc., have been developed over the past few years, currently, one method that can successfully track the intact nanocarriers in vivo directly is by Förster resonance energy transfer (FRET). This review summarizes the application of FRET as the in vivo nanoparticle tracker for studying the in vivo pharmacokinetics of the organic nanocarriers and gives elaborative details on the techniques utilized.
Shifting machine learning for healthcare from development to deployment and from models to data
Authors: Angela Zhang, Lei Xing, James Zou, Joseph C. Wu
Journal: Nature Biomedical Engineering (2022)

In the past decade, the application of machine learning (ML) to healthcare has helped drive the automation of physician tasks as well as enhancements in clinical capabilities and access to care. This progress has emphasized that, from model development to model deployment, data play central roles. In this Review, we provide a data-centric view of the innovations and challenges that are defining ML for healthcare. We discuss deep generative models and federated learning as strategies to augment datasets for improved model performance, as well as the use of the more recent transformer models for handling larger datasets and enhancing the modelling of clinical text. We also discuss data-focused problems in the deployment of ML, emphasizing the need to efficiently deliver data to ML models for timely clinical predictions and to account for natural data shifts that can deteriorate model performance. This Review discusses the use of deep generative models, federated learning and transformer models to address challenges in the deployment of machine learning for healthcare.
测试迪高替尼乳膏治疗慢性手部湿疹的不同剂量
Journal: British Journal of Dermatology (2022)

在本试验中，测试了四种不同的迪高替尼乳膏剂量，并与一种安慰剂乳膏 (看上去像测试药物但不含任何药物成分的乳膏) 进行了比较。本试验由 LEO Pharma 资助，在美国、德国和丹麦开展，入组了 250 多名受试者。
Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines
Authors: Takashi Nakamura, Yusuke Sato, Yuma Yamada, Mahmoud M. Abd Elwakil, Seigo Kimura, Mahmoud A. Younis, Hideyoshi Harashima
Journal: Advanced Drug Delivery Reviews (2022)
In patients with psoriasis, the types of microbes in the gut are different from those in healthy people
Journal: British Journal of Dermatology (2022)

Microbes living in our digestive tract contribute to human health by enabling us to digest essential nutrients, by protecting the intestinal barrier from infection and in developing the immune system. In patients with several inflammatory and auto‐immune diseases, researchers have found differences in the amount and type of different microbes in the gut compared with healthy individuals and these changes may contribute to the disease process. To date, studies of gut microbes in patients with psoriasis have been inconclusive; they have relied chiefly on cloning the microbial genes using a technique called rRNA sequencing analysis.
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study
Authors: Léo Plaçais, Stéphane Dalle, Olivier Dereure, Sabiha Trabelsi, Sophie Dalac, Delphine Legoupil, Henri Montaudié, Jean-Philippe Arnault, Julie De Quatrebarbes, Philippe Saiag, Florence Brunet-Possenti, Thierry Lesimple, Eve Maubec, François Aubin, Florence Granel-Brocard, Jean-Jacques Grob, Pierre-Emmanuel Stoebner, Clara Allayous, Bastien Oriano, Caroline Dutriaux, Laurent Mortier, Céleste Lebbe
Journal: Annals of the Rheumatic Diseases (2022)

Objective To quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma. Methods Case–control study performed on a French multicentric prospective cohort of patients with melanoma, matched for irAE risk factors and oncological staging. Risk of irAE was assessed by logistic regression. Results 110 patients with pAID were included and matched with 330 controls, from March 2013 to October 2020. Over a median follow-up period of 7.2 months for cases and 6.9 months for controls, the ORs of developing all-grade and grade ≥3 irAEs among cases compared with controls were 1.91 (95% CI (1.56 to 2.27)) and 1.44 (95% CI (1.08 to 1.82)), respectively. Patients with pAID had an increased risk of multiple irAEs (OR 1.46, 95% CI (1.15 to 2.67)) and a shorter time to irAE onset. In contrast, there were no difference in irAE-related mortality nor in the rate of treatment discontinuation, and a landmark analysis revealed a better survival at 24 months among cases (p=0.02). Thirty per cent of cases experienced a pAID flare during follow-up, and baseline immunosuppression did not prevent irAE occurrence. Last, we report associations between the pAID clinical subsets and organ-specific irAEs. Conclusion In our study, patients with pAID were at greater risk of all-grade, severe and multiple irAEs, yet had a better 24-month survival than controls. Thus, patients with pAID should be eligible for ICI therapy but benefit from a close monitoring for irAE occurrence, especially during the first months of therapy.
Letter to the editor: Risk factors of NAFLD in preterm and low birthweight. More questions than answers!
Authors: Nitisha Mondia, Satender Pal Singh, Ajay Kumar Mishra
Journal: Hepatology (2022)

To the editor: We read with interest the article by Amadou et al. on the association between birth weight, preterm birth, and NAFLD in a community‐based cohort.1 The study showed that premature birth (OR = 1.23; 95% CI, 1.03–1.48 for birth between 33 and 37 vs. ≥37 weeks) was associated with NAFLD. This study is important given that knowing neonate risk factors would help clinicians in the management and elimination of the future risk of NAFLD. However, certain issues need consideration. First, because the study took the birth health card as the retrospective data in a selected group of patients, the investigators did not mention hospital admission and duration of hospital stay at birth. Prolonged hospital admission requires artificial feeding; whether neonates received formula feeding or breast milk was also not mentioned. Previous studies have shown that neonates who were exclusively breastfed had a lower risk of developing subsequent NAFLD.2 Second, the study should also have discussed the weight chart in preterm, which is an important pillar of management, given that there is a tendency to overfeed at preterm, which predisposes neonates to “catch‐up growth.” Previous studies have shown that catch‐up growth is one of the risk factors for developing obesity as well as the future risk of NAFLD in preterm patients.3 Last, preterm neonates have an elevated risk of being born with other congenital, genetic, and metabolic disorders affecting multiple organs. The study by Amadou et al. indicates neither any genetic or metabolic risk factor nor the liver biopsy to rule out other metabolic disorders that may predispose neonates to NAFLD.4
Targeted erasure of DNA methylation by TET3 drives adipogenic reprogramming and differentiation
Authors: Jeu Park, Do Hoon Lee, Seokjin Ham, Jiyoung Oh, Jung-Ran Noh, Yun Kyung Lee, Yoon Jeong Park, Gung Lee, Sang Mun Han, Ji Seul Han, Ye Young Kim, Yong Geun Jeon, Han Nahmgoong, Kyung Cheul Shin, Sung Min Kim, Sung Hee Choi, Chul-Ho Lee, Jiyoung Park, Tae Young Roh, Sun Kim, Jae Bum Kim
Journal: Nature Metabolism (2022)
Does m-RNA vaccination protect from Sars-Cov2 (asymptomatic) infection in liver transplant recipients?
Authors: Ubaldo Visco Comandini, Marzia Montalbano, Raffaella Lionetti, Paola Piccolo, Daniela Nesticò, Silvia Meschi, Chiara Agrati, Chiara Taibi, Laura Vincenzi, Enrico Girardi, Giuseppe Maria Ettorre, Giampiero D’Offizi
Journal: Journal of Hepatology (2022)
Cerebrotendinous xanthomatosis: long-term course in 5 patients and first description of a successful pregnancy management during therapy with chenodesoxycholic acid (CDCA)
Authors: Jan Köhler, David Schoeler, Petra May, Linus Mrozek, Renate Kimmerle, Tom Lüdde, Stephan vom Dahl
Journal: Journal of Hepatology (2022)
Modeling ischemic cholangiopathy in human cholangiocyte organoid for screening of novel cholangio-protective agents
Authors: Shaojun Shi, Henk P. Roest, Marcel Bijvelds, Jeroen de Jonge, Hugo de Jonge, Jan Ijzermans, Monique M.A. Verstegen, Luc J.W. van der Laan
Journal: Journal of Hepatology (2022)
“Zero C” hospital project: an innovative screening and referral model in hospitalized patients at different divisions
Authors: Valerio Rosato, Loreta Kondili, Riccardo Nevola, Alessio Aghemo, Pasquale Perillo, Ruben Napolitano, Antonio Sciambra, Davide Mastrocinque, Ernesto Claar
Journal: Journal of Hepatology (2022)
Metabolomic profiling of capillary dry blood samples for the differential diagnoses of hepatocellular carcinoma and liver diseases
Authors: Philipp Brunnbauer, Jennifer Kirwan, Can Kamali, Christian Benzing, Katrin Splith, Karl Hillebrandt, Johann Pratschke, Moritz Schmelzle, Felix Krenzien
Journal: Journal of Hepatology (2022)
Multi-omics analysis of human livers reveals variation in intrahepatic inflammation across chronic hepatitis B infection phases
Authors: Noé Axel Montanari, Ricardo Ramirez, Abhishek Aggarwal, Nicholas Van Buuren, Michael Doukas, Christina Moon, Scott Turner, Lauri Diehl, Li Li, Jose Debes, Becket Feierbach, Andre Boonstra
Journal: Journal of Hepatology (2022)
A lower cut-off of liver stiffness measurement (8/13) kPa performs better than Baveno 6 criteria for advanced chronic liver disease in patients with non-alcoholic fatty liver disease
Authors: Sagnik Biswas, Manas Vaishnav, Piyush Pathak, Himanshu Narang, Shubham Mehta, Amit Goel, Shalimar
Journal: Journal of Hepatology (2022)
Early initiation of continuous renal replacement therapy improves renal outcomes and survival in patients with acute on chronic liver failure-a prospective cohort study
Authors: Rakhi Maiwall, Ashini Hidam, Sonia Kadyan, Mansi Singh, Anupam Kumar, Rajendra Mathur, Harshvardhan Tevethia, Hitesh Singh, Siva Tez Pv, Shiv Kumar Sarin
Journal: Journal of Hepatology (2022)
Modulation of the cholangiocarcinoma stem-like compartment by monounsaturated fatty acids
Authors: Giulia Lori, Chiara Raggi, Benedetta Piombanti, Mirella Pastore, Richell Booijink, Elisabetta Rovida, Jesper Andersen, Monika Lewinska, Paolo Montalto, Fabio Marra
Journal: Journal of Hepatology (2022)
Increased liver content of omega-3-derived lipid mediators associates with enhanced mitochondrial oxidative phosphorylation, fatty acid oxidation and metabolic efficiency
Authors: Cristina López-Vicario, David Sebastián, Mireia Casulleras, Marta Duran-Güell, Roger Flores-Costa, Ferran Aguilar, Juanjo Lozano, Ingrid Wei Zhang, Esther Titos, Jing X Kang, Antonio Zorzano, Makoto Arita, Joan Clària
Journal: Journal of Hepatology (2022)
Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different BCLC stages undergoing curative hepatectomy
Authors: Grace Lai-Hung Wong, Terry Cheuk-Fung Yip, Angus Wong, Brian Chan, Matthew Fong, Vincent Wai-Sun Wong, Stephen L. Chan, Kelvin Ng
Journal: Journal of Hepatology (2022)
TIPS with versus without variceal embolization for the prevention of variceal rebleeding: a randomized controlled trial
Authors: Yong Lv, Hui Chen, Bohan Luo, Wei Bai, Kai Li, Zhengyu Wang, Dongdong Xia, Wengang Guo, Xiaomei Li, Jie Yuan, Zhanxin Yin, Daiming Fan, Guohong Han
Journal: Journal of Hepatology (2022)
Consequences of Substitution Model Selection on Protein Ancestral Sequence Reconstruction
Authors: Roberto Del Amparo, Miguel Arenas
Journal: Molecular Biology and Evolution (2022)

Abstract The selection of the best-fitting substitution model of molecular evolution is a traditional step for phylogenetic inferences, including ancestral sequence reconstruction (ASR). However, a few recent studies suggested that applying this procedure does not affect the accuracy of phylogenetic tree reconstruction. Here, we revisited this debate topic by analyzing the influence of selection among substitution models of protein evolution, with focus on exchangeability matrices, on the accuracy of ASR using simulated and real data. We found that the selected best-fitting substitution model produces the most accurate ancestral sequences, especially if the data present large genetic diversity. Indeed, ancestral sequences reconstructed under substitution models with similar exchangeability matrices were similar, suggesting that if the selected best-fitting model cannot be used for the reconstruction, applying a model similar to the selected one is preferred. We conclude that selecting among substitution models of protein evolution is recommended for reconstructing accurate ancestral sequences.
PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterogygotes
Authors: Sona Frankova, Zuzana Rabekova, Magdalena Neroldova, Ondrej Fabian, Martin Kveton, Jaroslav A. Hubacek, Julius Spicak, Vera Adamkova, Milan Jirsa, Jan Sperl
Journal: Journal of Hepatology (2022)
Molecular insights into the tumour suppressor role of Protein Phosphatase 2A B56 delta complex in human liver, and its clinically relevant inhibition by cancerous inhibitor of PP2A
Authors: Judit Domenech Omella, Bob Meeusen, Emanuela Cortesi, Karen Zwaenepoel, Rita Derua, Chris Verslype, Patrick Pauwels, Jukka Westermarck, Tania Roskams, Jos van Pelt, Veerle Janssens
Journal: Journal of Hepatology (2022)
Automated FIB-4 calculator and targeted provider education improved referral of at-risk fibrotic NAFLD patients
Authors: Cindy Piao, Elvis Arteaga, Connor Reilly, Jesse Simpson, Ryan Peck, Trevor Pratt, Troy Peterson, Mopelola Adeyemo, Shuai Chen, Aili Guo, Scott MacDonald, Souvik Sarkar
Journal: Journal of Hepatology (2022)
MR-derived metrics have utility in identifying paediatric patients with stable autoimmune hepatitis
Authors: Piotr Pawliszak, Elizabeth Shumbayawonda, Jędrzej Sarnecki, Paulina Opyrchał, Kamil Janowski, Piotr Socha, Małgorzata Wozńiak, Elżbieta Jurkiewicz
Journal: Journal of Hepatology (2022)
Role of NAFLD-associated genetic variants on renal function in patients with non-alcoholic fatty liver disease
Authors: Laura D’Erasmo, Francesco Baratta, Alessia Di Costanzo, Ilaria Umbro, Alessandra Colantoni, Nicholas Cocomello, Daniele Pastori, Marcello Arca, Francesco Angelico, Maria Del Ben
Journal: Journal of Hepatology (2022)
New insights from mapping of the mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation
Authors: Mikal Jacob Hole, Kristin Jorgensen, Kristian Holm, Malin Holm Meyer-Myklestad, Asle Wilhelm Medhus, Dag Henrik Reikvam, Alexandra Götz, Krzysztof Grzyb, Kirsten Muri Boberg, Tom Hemming Karlsen, Martin Kummen, Johannes R. Hov
Journal: Journal of Hepatology (2022)
A dynamic approach to modelling baseline disease status and ALT elevation over follow-up on clinical-event free survival in autoimmune hepatitis: a canadian multicentre cohort
Authors: Christina Plagiannakos, Gideon Hirschfield, Ellina Lytvyak, Surain Roberts, Marwa Ismail, Kattleya Tirona, Andrew L. Mason, Harry Janssen, Aliya Gulamhusein, Aldo J Montano-Loza, Bettina Hansen
Journal: Journal of Hepatology (2022)
Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)
Authors: Cynthia Levy, Stephen Caldwell, Parvez Mantry, Velimir Luketic, Charles Landis, Jonathan Huang, Edward Mena, Rahul Maheshwari, Kevin Rank, Jun Xu, Xiangyu Lu, Xiaomin Lu, Chuhan Chung, Robert Myers, Kris Kowdley
Journal: Journal of Hepatology (2022)
A new score to predict mortality at baseline in patients not fulfilling KCH criteria for non acetaminophen induced liver failure-The “SAFE” score (Severity of ALF in emergency)
Authors: Harshvardhan Tevethia, Rakhi Maiwall, Shalini Thapar, Roshan Koul, Prashant Mohan Agarwal, Guresh Kumar, Ashok Choudhury, Shiv Kumar Sarin
Journal: Journal of Hepatology (2022)
Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide-an interim analysis
Authors: Pin-Nan Cheng, Chun-Jen Liu, Jyh-Jou Chen, I-Cher Feng, Hsing-Tao Kuo, Pei-Lun Lee, Ming-Lung Yu, Yencheng Chiu, Chiu Hung-Chih, Shih-Chieh Chien, Pei-Jer Chen
Journal: Journal of Hepatology (2022)
HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection
Authors: Lisa Sandmann, Birgit Bremer, Cihan Yurdaydin, Katja Deterding, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, Benjamin Maasoumy
Journal: Journal of Hepatology (2022)
Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection- Insights from the D-LIVR trial
Authors: Ohad Etzion, Maria Buti, David Yardeni, Anat Nevo-Shor, Daneila Munteanu, Ingrid Choong, Lisa Weissfeld, Naim Abu-Freha, Rob Howard, Tarik Asselah, Pietro Lampertico
Journal: Journal of Hepatology (2022)
Treatment of hepatitis C in primary healthcare in the country of Georgia
Authors: Tengiz Tsertsvadze, Amiran Gamkrelidze, Nikoloz Chkhartishvili, Akaki Abutidze, Lali Sharvadze, Maia Butsashvili, David Metreveli, Lia Gvinjilia, Tinatin Kuchuloria, Shaun Shadaker, Tamar Gabunia, Ekaterine Adamia, Stefan Zeuzem, Nezam Afdhal, Sanjeev Arora, Karla Thornton, Paige A Armstrong
Journal: Journal of Hepatology (2022)
Closely monitored alpha-fetoprotein allows early detection of hepatocellular carcinoma recurrence after orthotopic liver transplantation
Authors: Magdalena Hahn, Adam Herber, Rami Al-Sayegh, Janett Fischer, Anne Olbrich, Sebastian Rademacher, Daniel Seehofer, Sebastian Ebel, Timm Denecke, Thomas Berg, Florian van Bömmel
Journal: Journal of Hepatology (2022)
Secular Trends in Risk Profiles Among Adults With Cardiovascular Disease in the United States
Authors: Yumin Gao, Nino Isakadze, Eamon Duffy, Qicong Sheng, Jie Ding, Zane T MacFarlane, Yingying Sang, Scott T McClure, Elizabeth Selvin, Kunihiro Matsushita, Seth S Martin
Journal: Journal of the American College of Cardiology (2022)
Targeting liver glutaminase 1 modulates hepatic ammonia in experimental Non-Alcoholic Steatohepatitis
Authors: Maria Mercado-Gómez, Naroa Goikoetxea, Marina Serrano-Macia, Sofia Lachiondo-Ortega, Rubén Rodríguez Agudo, Petar Petrov, Miren Bravo, Claudia Gil-Pitarch, Irene González-Recio, Jorge Simón Espinosa, María Luz Martínez-Chantar, Teresa Cardoso Delgado
Journal: Journal of Hepatology (2022)
RNA-Seq based transcriptome analysis revealed inhibiting methionine aminopeptidase 2 prevented hepatocellular carcinoma with inhibited angiogenesis
Authors: Yongtao Wang, Mozhdeh Sojoodi, Shijia Zhu, Wei Tang, Guoliang Qiao, Shike Wang, Stephen Barrett, Michael Lanuti, Motaz Qadan, Yujin Hoshida, Kenneth K. Tanabe
Journal: Journal of Hepatology (2022)